MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

Search

AbbVie Inc

Cerrado

SectorSalud

192.65 3.42

Resumen

Variación precio

24h

Actual

Mínimo

187.3

Máximo

193.07

Métricas clave

By Trading Economics

Ingresos

-1.6B

-23M

Ventas

642M

15B

P/B

Media del Sector

71.496

57.333

BPA

2.16

Rentabilidad por dividendo

3.86

Margen de beneficio

-0.152

Empleados

55,000

EBITDA

-4.4B

535M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+14.67% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.86%

2.63%

Próximas Ganancias

24 jul 2025

Fecha Próximo Dividendo

15 may 2025

Próxima Fecha de Ex Dividendo

14 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-29B

306B

Apertura anterior

189.23

Cierre anterior

192.65

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

AbbVie Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

25 abr 2025, 13:57 UTC

Ganancias

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 abr 2025, 12:52 UTC

Ganancias

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

9 abr 2025, 18:18 UTC

Principales Movimientos del Mercado

Pharma Shares Reverse Losses After Tariff Pause

9 abr 2025, 09:39 UTC

Principales Movimientos del Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

27 feb 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12 feb 2025, 13:41 UTC

Principales Movimientos del Mercado

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

28 abr 2025, 12:44 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 abr 2025, 09:33 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 abr 2025, 16:03 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 abr 2025, 14:00 UTC

Principales Noticias
Ganancias

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 abr 2025, 12:24 UTC

Principales Noticias
Ganancias

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 abr 2025, 12:03 UTC

Principales Noticias
Ganancias

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q International HUMIRA Rev $377M >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Global Skyrizi Rev $3.43B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Net $1.29B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Global IMBRUVICA Rev $738M >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q EPS 72c >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Adj EPS $2.46 >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Rev $13.34B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie Sees FY Adj EPS $12.09-Adj EPS $12.29 >ABBV

14 mar 2025, 09:30 UTC

Principales Noticias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3 mar 2025, 15:04 UTC

Adquisiciones, fusiones, absorciones

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 feb 2025, 13:25 UTC

Principales Noticias
Ganancias

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 feb 2025, 12:00 UTC

Ganancias

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5 feb 2025, 12:00 UTC

Principales Noticias

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31 ene 2025, 15:50 UTC

Principales Noticias
Ganancias

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31 ene 2025, 13:51 UTC

Ganancias

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

Comparación entre iguales

Cambio de precio

AbbVie Inc Esperado

Precio Objetivo

By TipRanks

14.67% repunte

Estimación a 12 meses

Media 213.35 USD  14.67%

Máximo 250 USD

Mínimo 190 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbbVie Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

14

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

176.97 / N/ASoporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.